Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : $69.3 million
Deal Type : Public Offering
Hyloris Pharmaceuticals Raises Approximately EUR 61.81 Million in Successful Initial Public Offering
Details : This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for gener...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 26, 2020
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : $69.3 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?
Reset All
